| Accession |
PRJCA020089 |
| Title |
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients |
| Relevance |
Medical |
| Data types |
Clinical trial data
|
| Organisms |
Homo sapiens
|
| Description |
There are unmet medical needs in patients who resist to EGFR TKIs, especially to osimertinib; APG-1252 shows synergy with osimertinib in both osimertinib treatment naive and resistant cell lines. This study is to explore the safety and efficacy of the combination of APG-1252 and osimertinib in 3rd generation TKI resistant patients and 3rd generation TKI treatment naive patients. |
| Sample scope |
Multiisolate |
| Release date |
2023-10-25 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Suzhou Yasheng Pharmaceutical Co., Ltd.
|
|
NA
|
|
|
|
| Submitter |
Yifan
Zhai (yzhai@ascentage.com)
|
| Organization |
Suzhou Yasheng Pharmaceutical Co., Ltd. |
| Submission date |
2023-09-25 |
